|Bid||3.27 x 1400|
|Ask||3.60 x 1000|
|Day's Range||3.40 - 4.29|
|52 Week Range||2.64 - 19.08|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The results indicate the design of the oral formulation achieves steady-state serum levels that surpass the therapeutic threshold- and better yet, within just 7 days' time. This is a colossal success against standard of care tamoxifen that needs a much slower 50 to 200-day period to achieve the same impact. Maxim analyst Jason Kolbert takes the news in confident stride, noting this is not only a quicker-paced delivery, but likewise the results demonstrate "higher" therapeutic drug levels.
Shares of pharmaceutical company Atossa Genetics Inc (NASDAQ:ATOS) are rising nearly 6% to $0.75 in Thursday's after-hours trading. The median time for patients in the study to reach the steady-state serum levels of Endoxifen while taking daily doses of Atossa’s oral Endoxifen was 7 days. Published literature indicates that it takes approximately 50-200 days for patients to reach steady-state Endoxifen levels when taking daily doses of oral tamoxifen.
High-growth stocks that are financially stable are attractive for many reasons. They provide a strong upside to your portfolio, with less likelihood of downside risks compared to less financially robustRead More...
Atossa Genetics may have taken a beating in the market yesterday after investors ran for the hills with fears of share dilution running wild after the breast cancer detection device maker revealed it needed to boost its cash flow. The expert cherry-picked to be added to Atossa's Scientific Advisory Board? Dr. Novina is one of the leading researchers in the field of RNAi therapeutics. He is an Associate Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School and an Associate Member of the Broad Institute of Harvard and MIT.
Shares of breast cancer detection device maker Atossa Genetics Inc (NASDAQ:ATOS) are tumbling nearly 23%, as of this writing. Atossa announced this morning that it will be selling approximately 5.3 million shares of its own stock to raise cash. Each share of common stock is being sold together with one Class A warrant and one Class B warrant at a combined effective price of $0.27. The warrants will be exercisable six months following the date of issuance and have an exercise price of $0.315.
Shares of Atossa Genetics Inc (NASDAQ:ATOS) tumbled 43% in morning trade Thursday, after the healthcare company's stock offering priced at a deep discount. The company said its follow-on offering of 11.50 million shares priced at $0.44, which is 48% below Thursday's closing price of $0.85. The Company has granted the underwriter an over-allotment option to purchase up to 1,000,000 additional shares of its common stock.
Today, Atossa Genetics Inc (NASDAQ:ATOS) investors are scratching their heads as to why the stock collapsed following the news that the company's breast cancer oral treatment Endoxifen delivered positive results from its Phase 1 study. You see, according to the principle of "buy the rumor, sell the news," the major catalyst for Atossa stock to rise has now been removed, and traders who were awaiting the clinical results have now reaped all the gains they're going to get from that particular catalyst. Atossa assessed safety, tolerability and the pharmacokinetics of proprietary formulations of both topical and oral Endoxifen dosage forms in varying dose levels over 28 days.
On October 2, Atossa Genetics (ATOS) announced a new program using Chimeric Antigen Receptor Therapy (CAR-T). The company plans to use its proprietary intraductal microcatheter technology to deliver CAR-T cells into the ducts of the breast for the potential targeted treatment of breast cancer. Chimeric antigen receptors (CAR-T) are engineered receptors, which graft an arbitrary specificity onto an immune effector cell (T cell).
In early April 2017, Atossa closed a public offering with gross proceeds to Atossa of approximately $4.4 million. The offering included 664,000 Class A Units at a public offering price of $0.75 per Class A Unit, which consisted of 664,000 shares of Common Stock and Warrants to purchase 664,000 shares of Common Stock. The offering also included 3,502 Class B Units at a public offering price of $1,000 per Class B Unit, which consisted of 3,502 shares of Series A Convertible Preferred Stock convertible into a total of 4,669,333 shares of Common Stock and Warrants to purchase 4,669,333 shares of Common Stock.